Home » Newsletters » BioWorld Science

BioWorld Science

June 15, 2018

View Archived Issues

Searching for a biomarker for microbiome rehabilitation in recurrent C. difficile infections

Apexigen and Yale Cancer Center enter a clinical collaboration

Faron Pharmaceuticals presents biomarker analysis of the phase III INTEREST trial

Luye Pharma initiates phase III trial of LY03005 in China

Ibulief I.V. Injection launched for patent ductus arteriosus in premature infants

Durvalumab shows promising PFS and tumor response rate in phase II DREAM study in mesothelioma

Diamyd Medical receives approval to initiate phase I/II study of Remygen

First participant dosed in phase II study of vosoritide in infants and young children

Arsanis outlicenses monoclonal antibodies targeting Klebsiella pneumoniae

Eisai subsidiary in joint nucleic acid drug discovery research program

BioClin Therapeutics presents first data from FIERCE-21 trial of B-701 plus docetaxel in mUCC

Responses seen with NY-ESO SPEAR T-cells in myxoid/round cell liposarcoma

Trillium initiates phase I trial of TTI-622 in lymphoma or myeloma

[177Lu]3BP-227 begins phase I/II trial in advanced solid tumors expressing NTSR1

FDA awards RMAT designation to Nightstar's NSR-REP1 for choroideremia

FDA confirms regulatory pathway for Resverlogix's apabetalone

Inozyme introduces genetic testing program for two rare calcification disorders

Temple University and Praeventix present 5-HT7 receptor ligands

NeuroVive Pharmaceutical patents protonophores for NAFLD

Researchers create animal model of ileal recurrence of postoperative Crohn's disease

ContraVir initiates clinical development program with CRV-431 for hepatitis B

ALK inhibitors presented by University of Michigan

3D Medicines divulges linifanib prodrugs for cancer

Georgia State University discloses TNF-alpha production inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...